NCT06678919 AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
| NCT ID | NCT06678919 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Arbeitsgemeinschaft medikamentoese Tumortherapie |
| Condition | Metastatic Colorectal Cancer (mCRC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-10-31 |
| Primary Completion | 2034-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2024-10-31 with a primary completion date of 2034-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States and Europe. Although selected patients with oligometastatic CRC undergo systemic therapy and surgery/local ablative therapy in curative intent, the treatment approach for the majority of metastatic CRC (mCRC) patients remains palliative with a median overall survival (OS) ranging between 9-38 months depending on various prognostic and predictive factors. Particularly in advanced stages (in the third line of therapy and beyond), interesting and promising results have recently been achieved with various treatment approaches. The aim of this registry is to establish a disease-specific registry to evaluate the treatment landscape of patients with mCRC who have already received at least two lines of therapy.
Eligibility Criteria
Inclusion Criteria: * patients ≥ 18 years with tissue-based diagnosis of mCRC * ≥ 2 prior lines of palliative systemic therapy including 5-FU, irinotecan, oxaliplatin, anti-VEGF, anti-EGFR (in case of RAS/BRAF wildtype), anti-PD1- therapy (in case of MSI/MMRd) . (Exception: Patients who have received mFOLFOXIRI +/- anti-VEGF or anti- EGFR- 1L therapy or patients with ineligibility to receive 5-FU, oxaliplatin or irinotecan can be included after 1st line.) Exclusion Criteria: * Due to the non-interventional design of this registry, there are no specific exclusion criteria
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06678919 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Colorectal Cancer (mCRC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06678919 currently recruiting?
Yes, NCT06678919 is actively recruiting participants. Contact the research team at office@agmt.at for enrollment information.
Where is the NCT06678919 trial being conducted?
This trial is being conducted at Linz, Austria, Linz, Austria, Rankweil, Austria, Salzburg, Austria and 3 additional locations.
Who is sponsoring the NCT06678919 clinical trial?
NCT06678919 is sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.